Fortress Biotech (NASDAQ:FBIO) is a biopharmaceutical company engaged in the acquisition, development and commercialization of pharmaceutical and biotechnology products. Through an innovative business model, it partners with a network of subsidiary companies to advance therapeutics across a range of therapeutic areas, including oncology, immunology, rare diseases and infectious diseases. The company seeks to leverage strategic collaborations, licensing agreements and internal research to build a diversified portfolio of pipeline assets.
The company’s product candidates encompass both clinical-stage and preclinical therapies. Key programs target solid tumors, hematologic malignancies, autoimmune conditions and neurological disorders. Fortress Biotech works with global partners to facilitate development and distribution, with ongoing clinical trials in North America, Europe and Asia. Commercial products are supported through specialty pharmacies, contract manufacturing organizations and strategic alliances aimed at optimizing patient access and supply chain efficiency.
Founded in 2006 and headquartered in Bay Harbor Islands, Florida, Fortress Biotech has grown through a series of partnerships and spin‐outs, fostering a collaborative ecosystem of affiliated biopharma companies. The leadership team is led by Chairman and Chief Executive Officer Lindsay A. Rosenwald, M.D., who brings extensive experience in biotechnology investing and product development. Senior management includes seasoned executives in regulatory affairs, clinical development, business development and corporate finance, guiding the company’s efforts to advance innovative therapies for unmet medical needs.
